Perioperative Management of Momelotinib for Minor Procedures
For patients on momelotinib undergoing minor surgical or invasive procedures, hold momelotinib for 3 days before and 3 days after the procedure, then resume once adequate wound healing is established.
Pre-Procedure Management
Timing of Drug Interruption
- Hold momelotinib 3 days (72 hours) before minor procedures 1
- This timing is based on guidance for ibrutinib (another JAK inhibitor) for minor surgical procedures, which provides a reasonable framework given the similar bleeding risk profile of JAK inhibitors 1
- The 3-day hold allows adequate clearance while minimizing the risk of disease flare, as momelotinib has a relatively short half-life 2
Pre-Procedure Assessment
- Obtain baseline complete blood count within 7-10 days before the procedure to assess for thrombocytopenia, anemia, and neutropenia 3, 4
- Evaluate platelet count specifically: Momelotinib can cause thrombocytopenia (25% any-grade incidence), which may increase bleeding risk 5
- Review concurrent antiplatelet or anticoagulant therapy: JAK inhibitors including momelotinib carry bleeding risk, particularly when combined with antiplatelet agents 1, 6
Post-Procedure Management
Timing of Drug Resumption
- Resume momelotinib 3 days after the minor procedure 1
- Ensure adequate wound healing before restarting: Look for absence of significant swelling, erythema, or drainage 7
- Confirm hemostasis is established: Typically requires 24-48 hours post-procedure for minor procedures 8, 9
Post-Procedure Monitoring
- Assess wound healing at 24-48 hours post-procedure before drug resumption 7
- Monitor for bleeding complications: Given the 23% incidence of any-grade bleeding with momelotinib 10, 5
- Check complete blood count 7-14 days after resuming therapy to monitor for cytopenias 4
Special Considerations
Bleeding Risk Factors
- Thrombocytopenia is the most common reason for momelotinib discontinuation (4% rate) 5
- Peripheral neuropathy (grade ≥2) is a contraindication in some clinical trials but occurs infrequently 3, 11
- Avoid concurrent warfarin: Momelotinib should not be given with warfarin due to increased bleeding risk 1
Disease-Specific Concerns
- Rapid disease progression can occur when JAK inhibitors are stopped: Minimize the treatment-free interval and resume as soon as safely possible 1
- For transfusion-dependent patients: Plan procedure timing to avoid periods of severe anemia 10, 12
Common Pitfalls to Avoid
- Do not extend the hold period unnecessarily: Prolonged interruption may lead to symptom recurrence and splenomegaly progression 10
- Do not resume if active infection is present: Bacterial infections occur in a significant proportion of patients (common adverse event) 6
- Do not overlook platelet count: Grade 3/4 thrombocytopenia occurs in 25% of patients and requires dose adjustment or further hold 5